You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

B-Cell receptor inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • BTK inhibitor
  • PD-1 inhibitor
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
May 20, 2023

Head Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Oral Cavity Squamous Cell Carcinoma Trial in Nashville

Not yet recruiting
  • Head and Neck Cancer
  • +9 more
  • Nashville, Tennessee
    Vanderbilt-Ingram Cancer Center
Aug 9, 2022

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

Colorectal Cancer, Hematologic Malignancy, Rectum Cancer Trial in Cleveland (Vactosertib, Fludarabine Phosphate,

Recruiting
  • Colorectal Cancer
  • +11 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Jan 18, 2023

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma Trial in Suzhou (Selinexor, Flu, CTX)

Recruiting
  • Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 3, 2022

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Head Cancer Trial in United States (IK-175 + nivolumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +5 more
  • IK-175 + nivolumab
  • Chicago, Illinois
  • +3 more
Jul 26, 2022

Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Suzhou (CD19/22 CART, Tislelizumab)

Unknown status
  • Relapsed Non Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 30, 2021

Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

Recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • Denver, Colorado
  • +19 more
Jan 27, 2023

Hepatitis B, Chronic Trial in Worldwide (JNJ-73763989, PD-1 inhibitor, Tenofovir Disoproxil)

Recruiting
  • Hepatitis B, Chronic
  • Vancouver, British Columbia, Canada
  • +31 more
Jan 17, 2023

Chronic Lymphocytic Leukemia Trial in United States (ABT-199)

Completed
  • Chronic Lymphocytic Leukemia
  • La Jolla, California
  • +14 more
Dec 29, 2021

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Autologous CD19-STAR-T cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Non Small Cell Lung Cancer Trial in Lyon (Cicaplast Balm B5, Dexeryl)

Completed
  • Head and Neck Squamous Cell Carcinoma
  • +3 more
  • Cicaplast Balm B5
  • Dexeryl
  • Lyon, Rhône, France
    Centre Léon Bérard
Jul 8, 2021

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023

Lymphomas, B-cell Lymphomas Trial in Houston (JV-213, Leukapheresis)

Not yet recruiting
  • Lymphomas
  • B-cell Lymphomas
  • Houston, Texas
    The University of Texas M D Anderson Cancer Center
Mar 6, 2023

Chronic Lymphocytic Leukemia Trial in Worldwide (Venetoclax)

Completed
Has Results
  • Chronic Lymphocytic Leukemia
  • Louisville, Kentucky
  • +66 more
Nov 9, 2022

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

Not yet recruiting
  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Fludarabine (30 mg/m^2)
  • +2 more
  • (no location specified)
Jul 25, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Multiple Myeloma, DLBCL, Glioblastoma Multiforme Trial in Worldwide (CC-223)

Completed
Has Results
  • Multiple Myeloma
  • +6 more
  • Los Angeles, California
  • +15 more
Dec 9, 2022

Cardiovascular Events Among Adults Relapsed or Refractory

Recruiting
  • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
  • +9 more
  • Electronic Health Record Review
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

Not yet recruiting
  • Relapsed Non-Hodgkin Lymphoma
  • +6 more
  • (no location specified)
Apr 12, 2023